Halozyme Therapeutics (HALO) Projected to Post Earnings on Tuesday

Key Points

• Halozyme Therapeutics is set to release its Q2 2025 earnings on August 5th, with analysts expecting $1.22 earnings per share and $282.66 million in revenue for the quarter.
• The company's CEO, Helen Torley, recently sold 20,000 shares of stock, indicating a 2.65% decrease in her ownership position.
• Recent analyst ratings for Halozyme show a mixture of opinions, with two analysts recommending a sell rating, while others maintain a hold or buy rating.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect Halozyme Therapeutics to post earnings of $1.22 per share and revenue of $282.66 million for the quarter. Halozyme Therapeutics has set its FY 2025 guidance at 5.300-5.700 EPS.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Halozyme Therapeutics's revenue for the quarter was up 35.2% compared to the same quarter last year. During the same period last year, the firm earned $0.79 earnings per share. On average, analysts expect Halozyme Therapeutics to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $1.03 during trading on Wednesday, hitting $60.08. The company had a trading volume of 1,427,045 shares, compared to its average volume of 1,242,595. The stock's 50-day moving average price is $54.96 and its 200 day moving average price is $57.61. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $70.50. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. The firm has a market capitalization of $7.40 billion, a P/E ratio of 15.98, a price-to-earnings-growth ratio of 0.39 and a beta of 1.15.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $41,403,763.17. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 60,000 shares of company stock valued at $3,262,400. Insiders own 2.40% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A hedge fund recently bought a new stake in Halozyme Therapeutics stock. Empowered Funds LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,832 shares of the biopharmaceutical company's stock, valued at approximately $755,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HALO. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $58.00 to $60.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. The Goldman Sachs Group initiated coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price target on the stock. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $62.70.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.